A Phase 3 clinical trial (NCT05641337) investigating Liraglutide as part of an optimal strategy for hypoglycemic therapy in patients with liver cirrhosis and diabetes reached primary completion on 2025-12-30. The trial, titled "Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes," was posted on ClinicalTrials.gov.
Background
Poor blood glucose control in patients with liver cirrhosis can worsen patient prognosis. With an increasing number of patients experiencing liver cirrhosis alongside metabolic abnormalities, optimizing treatment strategies for diabetes in this population is crucial. Traditional diabetes treatment in the context of liver cirrhosis often involves intensive insulin therapy, which is associated with a high incidence of hypoglycemia, significant blood sugar fluctuations, and the need for multiple injections. Research indicates that insulin therapy may be linked to increased overall mortality compared to non-insulin therapies in this specific patient group.
Trial design
The Phase 3 study (NCT05641337), titled "Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes," enrolled 184 participants. The trial investigated an optimal strategy of hypoglycemic therapy for individuals diagnosed with both liver cirrhosis and diabetes. The interventions listed for the study included insulin degludec and insulin aspart. The trial's primary outcomes have not yet been posted.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05641337, titled "Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes," was posted on 2025-12-30 on clinicaltrials.gov.